China (Mainland)
Hyodeoxycholic acid CAS NO.83-49-8
- FOB Price: USD: 10.00-10.00 /Gram Get Latest Price
- Min.Order: 10 Gram
- Payment Terms: T/T,Other
- Available Specifications:
99.5(10-200)Gram
- Product Details
Keywords
- Hyodeoxycholic acid
- 83-49-8
- high purity>99%
Quick Details
- ProName: Hyodeoxycholic acid
- CasNo: 83-49-8
- Molecular Formula: C8H11NO3
- Appearance: white powder
- Application: Pharmaceutical industry and research
- DeliveryTime: within 24hours
- PackAge: 10g,100g,1kg，25kg
- Port: Shanghai
- ProductionCapacity: 1000 Gram/Day
- Purity: 99.50%
- Storage: Dry preservation
- Transportation: Fedex,TNT,EMS,DHL
- LimitNum: 10 Gram
- Related Substances: 0.01%
- Residue on Ignition: 0.03
- Heavy Metal: 0.0004
- Valid Period: 7days
Superiority
in stock
Assay:99% white powder
dentification(HPLC) ：The retention time of the major peak in the chromatogram of the assay preparation corresponds to that in the chromatogram of the Conformal standard preparation, as obtained in the assay
Single impurities ≤0.1%
Total impurities ≤0.11% Wuhan Yingyuanbei Biotechnology Co., Ltd. is a high-tech enterprise specializing in R&D and production of pharmaceutical raw materials and intermediates.
At present, the company's research team is composed of dozens of high-tech personnel. At present, there is a great breakthrough in the research of raw materials for various cancers and complex diseases. It has been able to independently develop hundreds of pharmaceutical raw materials and intermediates, most of which have completed mass production.
Details
CBNumber: CB4257035
Bezeichnung: Aristolochic acid B
Summenformel: C16H9NO6
Molgewicht: 311.25
CAS-Nr.: 475-80-9
MOL-Datei: MOL-Datei
Wuhan Yingyuanbei Biotechnology Co., Ltd. is a high-tech enterprise specializing in R&D and production of pharmaceutical raw materials and intermediates.
At present, the company's research team is composed of dozens of high-tech personnel. At present, there is a great breakthrough in the research of raw materials for various cancers and complex diseases. It has been able to independently develop hundreds of pharmaceutical raw materials and intermediates, most of which have completed mass production.
